Indian Generic Drug Market Outlook 2020
Generics drugs are bioequivalent versions of the originator medicines. These drugs are cheaper and offer similar health benefits as those of branded counterparts. Generics are showing high penetration in the pharma market across the globe. In India, these drugs account for nearly 75% of the pharma market. This is due to the factors, such as rising healthcare expenditure, ageing population, high incidences of obesity, diabetes and cardiovascular diseases, as well as ongoing patent cliff of blockbuster drugs in the US and European markets. India is a market dominated by branded generics. Approximately 80% of the generics are off-patented drugs sold under brand names by big pharmaceutical companies like Pfizer, Bristol-Myer-Squibb and Glaxosmithkline among others. Branded generics are available at very high cost leading to affordability issues, particularly in rural india.
In the report “Indian Generic Drug Market Outlook 2020”, RNCOS analysts have endeavoured to address the current scenario of generics drug industry, factors favouring growth of the market, major roadblocks for the lack of penetration of unbranded drugs, and government initiatives to promote generic drugs. The report covers detailed description of the market size of generic drugs and its future forecast till 2020. Additionally, market segmentation of generic drugs by therapeutic segments is also included. RNCOS predicts that owing to the implementation of government schemes, like Jan Aushadhi, Free essential drug, and Sehat, the unbranded generic drug market is likely to show a promising growth in the near future. The generic drug market is anticipated to grow at a CAGR of 16.3% from 2014-2020.
The latter half of the report provides competitive landscape including the market shares of key players, such as Sun-Pharma, Dr. Reddys, Cipla, Lupin, Biocon, and others. Finally, a separate section comprising of opportunity assessment for the domestic generic manufactures is also added. The last part of the report describes several steps that need to be taken by the Government to promote unbranded drugs. On the whole, the report provides information that will prove to be vital for investors interested in the domestic market.
In the report “Indian Generic Drug Market Outlook 2020”, RNCOS analysts have endeavoured to address the current scenario of generics drug industry, factors favouring growth of the market, major roadblocks for the lack of penetration of unbranded drugs, and government initiatives to promote generic drugs. The report covers detailed description of the market size of generic drugs and its future forecast till 2020. Additionally, market segmentation of generic drugs by therapeutic segments is also included. RNCOS predicts that owing to the implementation of government schemes, like Jan Aushadhi, Free essential drug, and Sehat, the unbranded generic drug market is likely to show a promising growth in the near future. The generic drug market is anticipated to grow at a CAGR of 16.3% from 2014-2020.
The latter half of the report provides competitive landscape including the market shares of key players, such as Sun-Pharma, Dr. Reddys, Cipla, Lupin, Biocon, and others. Finally, a separate section comprising of opportunity assessment for the domestic generic manufactures is also added. The last part of the report describes several steps that need to be taken by the Government to promote unbranded drugs. On the whole, the report provides information that will prove to be vital for investors interested in the domestic market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. INDIA PHARMACEUTICAL MARKET OUTLOOK
4. DRIVERS
4.1 Rising Healthcare Expenditures
4.2 Increasing Disposable Incomes
4.3 Growing Ageing Population
4.4 Surging Lifestyle Diseases
4.4.1 Cardiovascular Diseases
4.4.2 Diabetes
4.4.3 Cancer
4.5 Ongoing Patent Cliff
5. CHALLENGES
5.1 Competition from Branded Drugs
5.2 Lack of Price-Control
5.3 Weak Supply Chain Management
5.4 Lack of Promotion
5.5 Quality Control
5.6 Lack of Awareness
6. SUPPLY CHAIN MODEL
7. REGULATORY LANDSCAPE
8. INDIA GENERIC OVERVIEW
8.1 Indian Market Performance Relative to the World
8.2 Market Size
8.3 Top Generic Drugs Globally
8.4 Major Generic Segments
9. CONSOLIDATIONS IN GENERICS INDUSTRY
10. GOVERNMENT INITIATIVES
10.1 Jan Aushadhi Scheme for the promotion of Generics Drugs
10.2 Free Essential Drug Scheme
10.3 Telemidicine Initiative “Sehat”
11. COMPETITION
11.1 Market Share of Major Players
11.2 Profiles
11.2.1 Sun Pharma
11.2.2 Cipla Limited
11.2.3 Biocon
11.2.4 Dr. Reddy’s Laboratories
11.2.5 Lupin Ltd.
11.2.6 Aurobindo Pharma Limited
11.2.7 Wockhardt
11.2.8 Zydus Cadila
11.2.9 Glenmark
11.2.10 Jubilant LifeSciences
12. FUTURE OUTLOOK
13. GENERIC INDUSTRY: THE ROAD AHEAD
13.1 Opportunities
13.2 Recommendations
2. RESEARCH METHODOLOGY
3. INDIA PHARMACEUTICAL MARKET OUTLOOK
4. DRIVERS
4.1 Rising Healthcare Expenditures
4.2 Increasing Disposable Incomes
4.3 Growing Ageing Population
4.4 Surging Lifestyle Diseases
4.4.1 Cardiovascular Diseases
4.4.2 Diabetes
4.4.3 Cancer
4.5 Ongoing Patent Cliff
5. CHALLENGES
5.1 Competition from Branded Drugs
5.2 Lack of Price-Control
5.3 Weak Supply Chain Management
5.4 Lack of Promotion
5.5 Quality Control
5.6 Lack of Awareness
6. SUPPLY CHAIN MODEL
7. REGULATORY LANDSCAPE
8. INDIA GENERIC OVERVIEW
8.1 Indian Market Performance Relative to the World
8.2 Market Size
8.3 Top Generic Drugs Globally
8.4 Major Generic Segments
9. CONSOLIDATIONS IN GENERICS INDUSTRY
10. GOVERNMENT INITIATIVES
10.1 Jan Aushadhi Scheme for the promotion of Generics Drugs
10.2 Free Essential Drug Scheme
10.3 Telemidicine Initiative “Sehat”
11. COMPETITION
11.1 Market Share of Major Players
11.2 Profiles
11.2.1 Sun Pharma
11.2.2 Cipla Limited
11.2.3 Biocon
11.2.4 Dr. Reddy’s Laboratories
11.2.5 Lupin Ltd.
11.2.6 Aurobindo Pharma Limited
11.2.7 Wockhardt
11.2.8 Zydus Cadila
11.2.9 Glenmark
11.2.10 Jubilant LifeSciences
12. FUTURE OUTLOOK
13. GENERIC INDUSTRY: THE ROAD AHEAD
13.1 Opportunities
13.2 Recommendations
LIST OF FIGURES:
Figure 3-1: Breakdown of India Pharmaceutical Market by Value (%) 2009-2014
Figure 3-2: Domestic Pharmaceutical Market (Billion US$) 2014-2020
Figure 4-1: Healthcare Expenditure (% of GDP) 2009-2014
Figure 4-2: Personal Disposable Income (Billion US$) 2009-2014
Figure 4-3: Population Above 65 Years (Million) 2009-2014
Figure 4-4: Diabetes Population (20-79 Years) Million 2013 & 2030
Figure 4-5: Number of Cancer Cases (‘000) 2014 & 2020
Figure 6-1: Generic Supply Chain
Figure 7-1: Hierarchy of Ministry for Generic Drug Regulation
Figure 8-1: Share of India in Global Generics Market (%) 2014
Figure 8-2: India Generics Drug Market (Billion US$) 2009-2014
Figure 8-3: Revenue Share of Major Generics Segments (%) 2014
Figure 11-1: Sun Pharma - Break up of Revenue by Therapeutic Segment (%), 2014
Figure 11-2: Sun Pharma - Break up of Revenue by Geography (%), 2014
Figure 11-3: Cipla Limited - Break up of Revenue by Geography (%), 2014
Figure 11-4: Biocon - Break up of Revenue by Geography (%), 2014
Figure 11-5: Dr. Reddy's Laboratories - Break up of Revenue by Geography (%), 2014
Figure 11-6: Lupin Limited - Revenues by Trade (Billion US$), 2014
Figure 11-7: Aurobindo Pharma Limited - Break up of Formulations Revenue of by Geography (%), 2014
Figure 11-8: Wockhardt - Break up of Revenue by Geography (%), 2014
Figure 11-9: Zydus Cadila - Break up of Revenue by Geography (%), 2014
Figure 11-10: Glenmark - Break up of Revenue by Geography (%), 2014
Figure 11-11: Jubilant LifeSciences - Break up of Revenue by Geography (%), 2014
Figure 12-1: Generics Drug Market (Billion US$) 2014-2020
Figure 3-1: Breakdown of India Pharmaceutical Market by Value (%) 2009-2014
Figure 3-2: Domestic Pharmaceutical Market (Billion US$) 2014-2020
Figure 4-1: Healthcare Expenditure (% of GDP) 2009-2014
Figure 4-2: Personal Disposable Income (Billion US$) 2009-2014
Figure 4-3: Population Above 65 Years (Million) 2009-2014
Figure 4-4: Diabetes Population (20-79 Years) Million 2013 & 2030
Figure 4-5: Number of Cancer Cases (‘000) 2014 & 2020
Figure 6-1: Generic Supply Chain
Figure 7-1: Hierarchy of Ministry for Generic Drug Regulation
Figure 8-1: Share of India in Global Generics Market (%) 2014
Figure 8-2: India Generics Drug Market (Billion US$) 2009-2014
Figure 8-3: Revenue Share of Major Generics Segments (%) 2014
Figure 11-1: Sun Pharma - Break up of Revenue by Therapeutic Segment (%), 2014
Figure 11-2: Sun Pharma - Break up of Revenue by Geography (%), 2014
Figure 11-3: Cipla Limited - Break up of Revenue by Geography (%), 2014
Figure 11-4: Biocon - Break up of Revenue by Geography (%), 2014
Figure 11-5: Dr. Reddy's Laboratories - Break up of Revenue by Geography (%), 2014
Figure 11-6: Lupin Limited - Revenues by Trade (Billion US$), 2014
Figure 11-7: Aurobindo Pharma Limited - Break up of Formulations Revenue of by Geography (%), 2014
Figure 11-8: Wockhardt - Break up of Revenue by Geography (%), 2014
Figure 11-9: Zydus Cadila - Break up of Revenue by Geography (%), 2014
Figure 11-10: Glenmark - Break up of Revenue by Geography (%), 2014
Figure 11-11: Jubilant LifeSciences - Break up of Revenue by Geography (%), 2014
Figure 12-1: Generics Drug Market (Billion US$) 2014-2020
LIST OF TABLES:
Table 4-1: List of Blockbustor Drugs Losing Patent (2015-2020)
Table 8-1: Similarities and Differences Between Branded & Generics Drugs
Table 8-2: Top Generic Drugs Globally by Prescription (Million) 2014
Table 9-1: Major Consolidations in Indian Generic Industry (2014-2015)
Table 10-1: Comparative analysis of Jan Aushadhi Scheme (2008 & 2013)
Table 10-2: Pricing Details of Medicines under JAS Scheme
Table 10-3: Free Drugs Provided by States
Table 11-1: Market Share of Key Generics Players (%), 2014
Table 11-2: Sun Pharma - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 11-3: Biocon - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 11-4: Dr. Reddy's Laboratories - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 11-5: Lupin Limited - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 11-6: Aurobindo Pharma Limited - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 11-7: Zydus Cadila - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 11-8: Glenmark - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 11-9: Jubilant LifeSciences - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 4-1: List of Blockbustor Drugs Losing Patent (2015-2020)
Table 8-1: Similarities and Differences Between Branded & Generics Drugs
Table 8-2: Top Generic Drugs Globally by Prescription (Million) 2014
Table 9-1: Major Consolidations in Indian Generic Industry (2014-2015)
Table 10-1: Comparative analysis of Jan Aushadhi Scheme (2008 & 2013)
Table 10-2: Pricing Details of Medicines under JAS Scheme
Table 10-3: Free Drugs Provided by States
Table 11-1: Market Share of Key Generics Players (%), 2014
Table 11-2: Sun Pharma - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 11-3: Biocon - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 11-4: Dr. Reddy's Laboratories - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 11-5: Lupin Limited - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 11-6: Aurobindo Pharma Limited - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 11-7: Zydus Cadila - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 11-8: Glenmark - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 11-9: Jubilant LifeSciences - Revenues by Business Segment (Billion US$), 2013 & 2014
